Using spectral CT scans for cervical cancer radiotherapy
The Clinical Research of Spectral CT in Radiotherapy for Cervical Cancer
This study is testing if special CT scans can help improve treatment planning and monitoring for patients with cervical cancer who are receiving chemotherapy and radiation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06433817 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the application of spectral computed tomography (CT) in the context of radiotherapy for patients with cervical cancer. It involves patients who have been diagnosed with cervical cancer and are undergoing concurrent chemoradiotherapy, with spectral CT scans being performed during both the arterial and venous phases. The study seeks to evaluate how spectral CT can enhance treatment planning and monitoring in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with cervical cancer who are receiving concurrent chemoradiotherapy.
Not a fit: Patients who have not undergone spectral CT scans or those with a history of allergy to intravenous contrast may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the precision of radiotherapy for cervical cancer patients, potentially leading to better treatment outcomes.
How similar studies have performed: While the application of spectral CT in radiotherapy is a relatively novel approach, there have been some preliminary studies suggesting its potential benefits in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All patients were confirmed cervical cancer by pathology 2. patients were treated with concurrent chemoradiotherapy 3. Spectral CT scans acquisition performed during the arterial phase and venous phase 4. All the patients underwent a 18F-FDG PET/CT before treatment Exclusion Criteria: 1. CT without spectral scans 2. History of allergy to intravenous contrast 3. Pregnant or potentially pregnant female subjects
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Fuquan Zhang, Porf
- Email: zhangfq@pumch.cn
- Phone: 86 01069154072
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.